Biology and regulation of IL-2: from molecular mechanisms to human therapy - PubMed (original) (raw)
Review
Biology and regulation of IL-2: from molecular mechanisms to human therapy
Rosanne Spolski et al. Nat Rev Immunol. 2018 Oct.
Abstract
IL-2 was first identified as a growth factor capable of driving the expansion of activated human T cell populations. In the more than 40 years since its discovery, a tremendous amount has been learned regarding the mechanisms that regulate the expression of both IL-2 and its cell surface receptor, its mechanisms of signalling and its range of biological actions. More recently, the mechanisms by which IL-2 regulates CD4+ T cell differentiation and function have been elucidated. IL-2 also regulates the effector and memory responses of CD8+ T cells, and the loss of IL-2 or responsiveness to IL-2 at least in part explains the exhausted phenotype that occurs during chronic viral infections and in tumour responses. These basic mechanistic studies have led to the therapeutic ability to manipulate the action of IL-2 on regulatory T (Treg) cells for the treatment of autoimmune disease and on CD8+ T cells for immunotherapy of cancer. IL-2 can have either positive or deleterious effects, and we discuss here recent ideas and approaches for manipulating the actions and overall net effects of IL-2 in disease settings, including cancer.
Similar articles
- Interleukin-2 as immunotherapeutic in the autoimmune diseases.
Orozco Valencia A, Camargo Knirsch M, Suavinho Ferro E, Antonio Stephano M. Orozco Valencia A, et al. Int Immunopharmacol. 2020 Apr;81:106296. doi: 10.1016/j.intimp.2020.106296. Epub 2020 Feb 12. Int Immunopharmacol. 2020. PMID: 32058934 Review. - IL-2 promotes the function of memory-like autoregulatory CD8+ T cells but suppresses their development via FoxP3+ Treg cells.
Shameli A, Yamanouchi J, Tsai S, Yang Y, Clemente-Casares X, Moore A, Serra P, Santamaria P. Shameli A, et al. Eur J Immunol. 2013 Feb;43(2):394-403. doi: 10.1002/eji.201242845. Epub 2013 Jan 15. Eur J Immunol. 2013. PMID: 23180662 - IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells.
Mostböck S, Lutsiak ME, Milenic DE, Baidoo K, Schlom J, Sabzevari H. Mostböck S, et al. J Immunol. 2008 Apr 1;180(7):5118-29. doi: 10.4049/jimmunol.180.7.5118. J Immunol. 2008. PMID: 18354238 - Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.
Ballesteros-Tato A. Ballesteros-Tato A. Immunotherapy. 2014;6(11):1207-20. doi: 10.2217/imt.14.83. Immunotherapy. 2014. PMID: 25496335 Free PMC article. Review. - CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis.
McNally A, Hill GR, Sparwasser T, Thomas R, Steptoe RJ. McNally A, et al. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7529-34. doi: 10.1073/pnas.1103782108. Epub 2011 Apr 18. Proc Natl Acad Sci U S A. 2011. PMID: 21502514 Free PMC article.
Cited by
- Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control.
Quixabeira DCA, Zafar S, Santos JM, Cervera-Carrascon V, Havunen R, Kudling TV, Basnet S, Anttila M, Kanerva A, Hemminki A. Quixabeira DCA, et al. Front Immunol. 2021 May 18;12:674400. doi: 10.3389/fimmu.2021.674400. eCollection 2021. Front Immunol. 2021. PMID: 34084172 Free PMC article. - Cytokine-mediated immunomodulation of osteoclastogenesis.
Zhou P, Zheng T, Zhao B. Zhou P, et al. Bone. 2022 Nov;164:116540. doi: 10.1016/j.bone.2022.116540. Epub 2022 Aug 27. Bone. 2022. PMID: 36031187 Free PMC article. Review. - HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
Liu Y, Li X, Zhang H, Zhang M, Wei Y. Liu Y, et al. Oncogene. 2021 Mar;40(12):2230-2242. doi: 10.1038/s41388-021-01689-6. Epub 2021 Mar 1. Oncogene. 2021. PMID: 33649535 Free PMC article. - The JAK-STAT pathway: from structural biology to cytokine engineering.
Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, Zhang J, Mi P, Kobe B, Wang F. Lv Y, et al. Signal Transduct Target Ther. 2024 Aug 21;9(1):221. doi: 10.1038/s41392-024-01934-w. Signal Transduct Target Ther. 2024. PMID: 39169031 Free PMC article. Review. - Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.
Wu Q, Qian W, Sun X, Jiang S. Wu Q, et al. J Hematol Oncol. 2022 Oct 8;15(1):143. doi: 10.1186/s13045-022-01362-9. J Hematol Oncol. 2022. PMID: 36209184 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials